Showing 1-10 of about 164 articles.
Paratek Pharmaceuticals
-- Approximately One Third of Commercial Lives in U.S. had Access to NUZYRA by the End of the First Quarter 2019 -- -- Significant Presence at ECCMID 2019 with Nine NUZYRA Presentations -- BOSTON,...
Paratek Pharmaceuticals
BOSTON, April 30, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...
Paratek Pharmaceuticals
- New microbiology data reinforce activity of NUZYRA against broad range of pathogens commonly associated with community-acquired infections - Study supports no dose adjustments in patients based on...
Paratek Pharmaceuticals
BOSTON, April 04, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...
Paratek Pharmaceuticals
BOSTON, April 01, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...
Paratek Pharmaceuticals
BOSTON, March 28, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...
Paratek Pharmaceuticals
BOSTON, March 18, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...
Paratek Pharmaceuticals
BOSTON, March 01, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...
Paratek Pharmaceuticals
BOSTON, March 01, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...
Paratek Pharmaceuticals
-- NUZYRA™ (omadacycline) Launched in the United States for the Treatment of CABP and ABSSSI -- -- New England Journal of Medicine Publishes Results from Two Pivotal Phase 3 Studies of NUZYRA -- --...
Showing 1-10 of about 164 articles.
